Treosulfan is a water-soluble structural analog of busulfan, acting as a prodrug of alkylating epoxide species. It does not induce severe hepatotoxicity or veno-occlusive disease at or above the maximum tolerated dose, lacks significant nonhematological toxicity and has a limited organ toxicity. It is mainly indicated for the treatment of patients with ovarian cancer. In the present study, we report that permanent donor-specific tolerance and stable mixed multilineage chimerism can successfully be achieved across haploidentical MHC barriers when Treosulfan is administered in combination with anti-T-cell mAb and T-celldepleted donor bone marrow cells. Furthermore, we show that less T-cell suppression is required when Treosulfan is included in the conditioning regimen. In conclusion, Treosulfan is a well-tolerated myeloablative agent with a low toxicity, and is a promising candidate drug for conditioning prior to bone marrow transplantation.
induction; myeloablation Solid organ transplantation has recently shown good progress due to the successful usage of immunosuppressive agents, which prevent acute rejection of the graft. However, these drugs suppress the immune system nonspecifically, leading to a higher susceptibility for opportunistic infections and malignancies, [1] [2] [3] whereas the continuous risk of chronic rejection remains and the life-long administration of these nonspecific immunosuppressive agents is required. Therefore, the induction of permanent donor-specific tolerance is a major goal in organ transplantation. A very effective method for the induction of donor-specific tolerance is the establishment of mixed hematopoietic chimerism, where host and donor hematopoietic cell populations coexist in the recipient. 4, 5 In mixed chimeras, both host and donor pre-thymocytes home to the thymus where T cells, responsive to both host and donor antigens (Ag), are eliminated via negative selection, in which both host and donor antigen-presenting cells are involved. 5 This results in a T-cell repertoire that is tolerant to Ag from both host and donor and in which the risk for graft-versus-host and host-versus-graft disease is strongly reduced. However, more importantly, once stable mixed chimerism is achieved, no additional immunosuppressive regimens are required.
Previously, we have developed a murine model in which stable mixed chimerism and donor-specific tolerance is induced over complete MHC barriers. This conditioning regimen involves a single dose of T-cell-directed monoclonal antibodies (mAb), sublethal total body irradiation (TBI) and the transplantation of T-cell-depleted allogeneic bone marrow cells (BMC). [6] [7] [8] Mice treated via this welltolerated and nonlethal regimen become stable mixed multilineage chimeric. [6] [7] [8] In addition, conditioning via this regimen enables the permanent acceptance of vascularized allografts as well as skin grafts. 9 Although the exact long-term risk to a patient receiving a sublethal dose of TBI is presently unknown, it may be associated with substantial morbidity. It would therefore be desirable to eliminate TBI from a clinical tolerance protocol. To design a clinically more applicable conditioning regimen, we investigated whether Treosulfan can replace TBI in our current model. Treosulfan (L-treitol 1,4-bismethanesulfonate, Ovastat s ) is a water-soluble prodrug of a bifunctional alkylating cytostatic and has mainly been used in the therapy of advanced ovarian cancer. [10] [11] [12] [13] Treosulfan caused only moderate side effects in patients, but these were manageable and rapidly reversible. 13, 14 Recently, we have shown that Treosulfan can be used to induce donor-specific tolerance over complete MHC barriers using either T-cell-depleted BMC or hematopoietic stem cells. 15 However, because of the HLA matching policies widespread in kidney transplant centers, kidney transplantation across a full HLA disparity hardly ever occurs. Therefore, we investigated in the present study whether the administered dose of Treosulfan can further be decreased to induce tolerance across haploidentical MHC barriers. We clearly demonstrate that stable mixed multi-lineage chimerism and donor-specific tolerance are induced when Treosulfan replaces TBI in our bone marrow transplantation (BMT) model. Indeed, these doses are lower than in BMT experiments over complete MHC barriers. 15 Furthermore, we investigated whether the dose of anti-CD3 mAb could be reduced. Besides the release of beneficial factors that enhance the engraftment of BMC, 16 this mAb has also undesired, but reversible, side effects. 17 We show here that a reduction in anti-CD3 administration, in combination with a diminished triple dose of Treosulfan and BMT over haploidentical MHC barriers leads toward a BMT model that is very promising for clinical purposes.
Materials and methods

Animals
In all, 8-to 14-week-old male C57BL/10 (B10, H-2 b ) and B10.BR (H-2 k ) mice were used as recipients and third parties, respectively. H-2 b/d F1 hybrids (F1) were used as donors and were obtained by crossing C57BL/10 females with B10.D2 males. Male B10.D2 (H-2 d ) mice were used as donors in fully MHC mismatched transplantation experiments. Recipient C57BL/10 mice were obtained from Harlan (Horst, The Netherlands), whereas all other animals were bred in the Central Animal Laboratory of the National Institute of Public Health and the Environment. All mice were maintained at the Animal Facility of the Central Animal Laboratory under specific pathogen-free conditions.
Monoclonal antibodies
Anti-CD3, a hamster IgG mAb produced from hybridoma 145-2C11 that is reactive against the CD3-e chain of the murine TCR, 18 was generously provided by Dr JA Bluestone (University of Chicago, Chicago, IL, USA). The mAb was purified on a protein A-sepharose column. The rat IgG2b mAb GK1.5, directed against the CD4 antigen (anti-CD4, American Type Culture Collection, Rockville, MD, USA), was purified using high-performance liquid chromatography (HPLC, Perkin-Elmer Series 410) with an ABX ion-exchange column, especially suited for antibody binding. Eluted mAbs were dialyzed against PBS, sterilized through a 0.22 mm filter (Millipore Corporation, Bedford, MA, USA), and frozen at -201C until used. Concentration was determined by absorbance at 280 nm. The purity of the mAbs was confirmed by SDS-PAGE.
Preparation of cell suspensions
Using sterile procedures, BMC were obtained by flushing femoral and tibial bones from donor mice with Iscove's modified Dulbecco's medium (IMDM; Life Technologies, Paisley, Scotland) supplemented with 10% heat inactivated fetal calf serum (FCS; Hyclone, Utah, USA), 2-mercaptoethanol (2 Â 10 À5 M), penicillin (100 IU/ml) and streptomycin (100 mg/ml). After lysis of erythrocytes with an ammonium chloride buffer, BMC were depleted of T cells by treatment with anti-Thy-1.2 mAb (F7D5; Serotec, Wiesbaden, Germany) and complement (low tox M rabbit complement, Cedarlane, Hornby, Ontario, Canada).
Preparation of chimeras
To induce long-term stable mixed multilineage chimerism, recipient mice received a single dose of 6 Gy TBI on day 0, or were treated on day À3, À2 and À1 with Treosulfan (Ovastat s , a generous gift from medac, Hamburg, Germany). On day 0, a single dose of 400 mg anti-CD3 was given intraperitoneally (i.p.). Subsequently, recipient animals were reconstituted on day 0 with 15 Â 10 6 T-celldepleted donor BMC. BMC were injected via the lateral tail vein using 0.2 ml of saline containing 5% heat-inactivated autologous serum. On day -1, recipient mice were given 500 mg of GK1.5 i.p., a CD4
þ T-cell-depleting mAb, in order to reduce the contribution of CD4 þ T cells to the 'cytokine release syndrome', which is associated with anti-CD3 treatment. 17 Flow cytometry analysis Donor cell engraftment was determined by flow cytometry using a FACS Calibur (Becton Dickinson, Mountain View, CA, USA). All procedures were performed in FACS buffer, containing 1% bovine serum albumin and 5 mM EDTA. Fluorescence data were collected using logarithmic amplification on 10 000 viable cells as determined by forward light scatter intensity. 
Skin transplantation
After completing the conditioning regimen, tail skin transplantation was performed. Each recipient was given a control syngeneic (B10), a donor (F1) and a third party (B10.BR) skin graft 6 weeks after BMC transfusion. The grafts were inspected three times a week and were considered to be rejected when no viable donor skin was detectable.
ELISPOT
Enzyme-linked immunospot assay (ELISPOT) was performed using a ELISPOT detection kit for mouse IFN-g (Diaclone, Besancion, France). Spleen cells from chimeric mice were incubated for 7 days with irradiated (20 Gy) recipient (B10), donor (F1) or third party (B10.BR) spleen cells in a 1:1 ratio. Next, ELISPOT was performed according to the manufacturer's recommendations. Hundred thousand to 5 Â 10 5 spleen cells from chimeric mice were incubated for 24 h with 1 Â 10 5 irradiated (20 Gy) untreated host, donor or third party spleen cells in a PVDF 96-well plate (Milipore Corporation, Bedford, MA, USA). All samples were tested in triplicates and in two dilutions.
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Results
Induction of donor-specific tolerance across haploidentical MHC barriers
To confirm that donor-specific tolerance can be induced over haploidentical MHC barriers using our sublethal conditioning regimen, sublethally irradiated (6 Gy) recipient (B10) mice were treated once with anti-T-cell mAbs, and subsequently 15 Â 10 6 haploidentical T-cell-depleted donor (F1) BMC were infused. At several time points after BMT, donor chimerism was measured. All transplanted mice (n ¼ 6) developed stable mixed multilineage chimerism throughout the lifetime of the animals (on average 72% at 14 weeks after BM transplantation; Figure 1 ), without any clinical signs of graft-versus-host disease. Both donorderived (F1) and control recipient-derived (B10) skin grafts were permanently accepted (4100 days), whereas third party skin grafts were rejected (median survival time (MST) 18 days; data not shown), indicating that donor-specific tolerance had been established in vivo. In addition, spleen cells of chimeric mice did not react against donor-type cells, but did react to third party targets in vitro as was assessed by ELISPOT (data not shown).
Infusion of F1 (H-2 b/d ) donor BMC in combination with a low dose of Treosulfan leads to reproducible donor chimerism
To investigate whether Treosulfan can substitute TBI in our tolerance model, recipient B10 mice were pretreated with various doses of Treosulfan on three consecutive days (day -3 until day -1) prior to T-cell-depleted donor (F1) BMT on day 0. Chimerism was measured at multiple time points after BMT. All mice treated with triple doses of 2000 , 1500 or 1000 mg/kg Treosulfan became stable mixed multilineage chimeric (Figure 2 ). However, we observed a gradual decrease in donor chimerism, when the dose of Treosulfan was reduced from 2000 to 1000 mg/kg (Table 1) . When the dose of Treosulfan was lowered to 750 or 500 mg/ kg, the incidence of donor chimerism was respectively 4/5 and 3/5. This decrease in Treosulfan also leads to larger variations in the percentage of donor chimerism between the individual animals ( Table 1) .
Induction of donor-specific tolerance in vivo and in vitro with F1 (B10 Â B10.D2) BMC
To examine the establishment of donor-specific tolerance in vivo, tail skin transplantations were performed on mice that underwent the sublethal conditioning regimen with Treosulfan and donor (F1) BMC. All mice received recipient (B10)-, donor (F1)-and third party-type (B10.BR) skin grafts. Mixed chimeric mice permanently accepted donor-derived skin grafts (4100 days) and rejected third party grafts within 21 days (MST 21 days; Figure 3a ). In addition, recipient-type (B10) skin grafts were also permanently accepted.
To evaluate the establishment of donor-specific tolerance in vitro of mixed chimeras that were treated with 1000 mg/ kg Treosulfan, anti-T-cell mAbs and BMC, an IFN-g ELISPOT assay was performed. Spleen cells from chimeras produced less spots per 10 6 cells upon incubation with donor-type (F1) cells compared to spleen cells from nonchimeras and control (B10) mice (92, 456 and 417 spots per 10 6 cells, respectively; Figure 3b ). In contrast, no significant difference was found in the frequency of reactive spleen cells between mixed chimeras, nonchimeras and untreated control mice upon incubation with third party cells (B10.BR; 391, 418 and 326 spots per 10 6 cells, respectively).
Treosulfan allows lower concentrations of anti-CD3 to establish donor-specific tolerance Anti-CD3 treatment has undesired side effects, among which is the 'cytokine release syndrome'. 17 To mitigate the contribution of CD4 þ T cells to this syndrome, recipients received an anti-CD4 mAb (GK1.5). To further diminish the side effects that are related to anti-CD3 treatment, we investigated whether the dose of anti-CD3 could be decreased in the conditioning regimen for BMT over haploidentical MHC barriers.
Recipient mice were treated with the lowest triple dose of Treosulfan that still resulted in mixed chimerism in 100% of the recipients (ie 1000 mg/kg). In addition, 15 Â 10 6 T-cell-depleted BMC and a single dose of anti-CD4 mAb were administered. Subsequently, each recipient received a single dose of anti-CD3 according to the group in which the recipient was placed (Table 2 ). Mice in group 1 received a single dose of 400 mg anti-CD3, mice in group 2 375 mg, mice in group 3 350 mg and finally the mice in group 4 Skin graft tolerance across haploidentical MHC barriers M van Pel et al received 325 mg anti-CD3. Donor chimerism was measured at several time points after BM transplantation. After i.p. administration of 400, 375, 350 and 325 mg anti-CD3, the incidence of chimerism was 6/6, 5/5, 3/5 and 5/5, respectively. All mixed chimeras were donor-specific tolerant in vivo, since donor-type (F1) skin grafts were permanently (4100 days) accepted and third party skin grafts were rapidly rejected (MST 18 days for 375 mg anti-CD3; Figure 4a ). Nonchimeras rejected both donor and third party skin grafts within 21 days. In addition, donorspecific tolerance was confirmed in vitro by IFN-g ELI-SPOT (Figure 4b ). Spleen cells from chimeras produced less spots per 10 6 cells upon incubation with donor-type (F1) cells compared to spleen cells from nonchimeras and control (B10) mice (46, 249 and 417 spots per 10 6 cells, respectively; Figure 4b ). In contrast, no difference was found in the frequency of reactive spleen cells between mixed chimeras, nonchimeras and untreated control mice upon incubation with third party cells (B10.BR; 186, 104 and 326 spots per 10 6 cells, respectively).
Discussion
Previously, we have developed a murine model in which stable mixed multilineage chimerism and donorspecific tolerance are induced over complete MHC barriers. [6] [7] [8] This model has clinical potential, but mice in this regimen undergo TBI to allow BMC engraftment. Although the exact long-term risk to a patient receiving a sublethal dose of TBI is presently unknown, it may be associated with substantial morbidity. Therefore we created a radiation-free conditioning regimen that is In the upper panels, control unmanipulated recipient (B10, H-2 dÀ ) and donor (F1, H-2 d þ ) are shown. The lower panels show a representative chimera at weeks 6 and 11 after BMT (a). Donor chimerism in mice treated with 1000 mg/kg Treosulfan, anti-T-cell mAbs and F1-BMC is mixed and multilineage. Determination of donor-derived (H-2 b/d þ ) myeloid (Gr-1 and CD11b) and lymphoid (B220 and Thy-1.2, also subdivided in CD4 and CD8 subpopulations) cell subsets in a representative chimera 11 weeks after BMT (b). Recipient mice received additionally 500 mg anti-CD4 mAb on day -1, and 400 mg anti-CD3 mAb on day 0.
Skin graft tolerance across haploidentical MHC barriers M van Pel et al based on our previous model, but in which Treosulfan replaces TBI. Treosulfan is a prodrug of a bifunctional alkylating cytostatic and is indicated for treatment of patients with ovarian carcinoma. 10, 19 Treosulfan does not induce severe hepatotoxicity or veno-occlusive disease in patients treated at or above the maximum tolerated dose, lacks significant nonhematological toxicity and has limited organ toxicity. 10, 20, 21 The busulfan derivative Treosulfan has been shown to deplete hematopoietic progenitor cells more effectively than busulfan in vitro, but to have poor activity in vivo when applied as a single dose. 22 However, efficient stem cell toxicity against committed and primitive stem cells was evident when fractionated, and escalating doses of Treosulfan were administered before BMT. 23, 24 Because of its lower toxicity compared to busulfan and its low nonhematological toxicity, Treosulfan is a good candidate drug for myeloablation prior to BMT or HSCT as a method for the induction of mixed hematopoietic chimerism and donorspecific tolerance.
Previously, we have shown that three daily doses of 1500 mg/kg Treosulfan, in combination with anti-T-cell mAbs and the transplantation of fully MHC disparate BMC, can induce stable mixed multilineage chimerism and donor-specific tolerance. 15 However, because of the HLA matching policies widespread in kidney transplant centers, kidney transplantation across a full HLA disparity almost never occurs. Therefore, we investigated in the present study whether Treosulfan can be used to induce tolerance over haploidentical MHC barriers. We clearly show that the dose of Treosulfan can be decreased to 3 Â 1000 mg/kg to induce reproducibly stable mixed multilineage chimerism and donor-specific tolerance over haploidentical transplantation barriers. This dose was used successfully in the treatment of human ALL models established in NOD/ SCID mice. 25 Besides a strong antileukemic activity, a reversible hematotoxic side effect was obvious in the treated animals. Doses of 3 Â 1500 mg/kg Treosulfan, however, demonstrated strong myeloablative potential in mice. 26 The use of Treosulfan allows another adjustment to our conditioning regimen, namely the dose of anti-CD3 mAb. The hamster mAb 145 2C11 that specifically recognizes the e chain of the murine CD3 molecule is a potent immunosuppressant. 18 It induces both depletion of CD3 þ cells and antigenic modulation of the CD3/TCR complex without physical disappearance of the cells. 6, 17, 27 Anti-CD3 treatment alone has undesired, but reversible, side effects like the 'cytokine-release syndrome', somnolence, hyporeactivity and diarrhea. 17 To mitigate these side effects, GK1.5, a CD4 þ T-cell-depleting mAb, is administered. Previously, in our TBI-BMT model, it was shown that when lower doses than 400 mg of anti-CD3 were injected, no stable chimerism was achieved and donor grafts were rejected. 6 This is not only because T cells are insufficiently suppressed, but also because anti-CD3 results in the release Table 2 Effect of a decreasing dose of anti-CD3 mAb on the induction of mixed chimerism after conditioning with 3 Â 1000 mg/kg Treosulfan, anti-CD4 mAb and F1-B10 BMT of factors that enhance the engraftment of BMC. 16 In BMT experiments across complete MHC barriers in combination with Treosulfan, we found that the dose of anti-CD3 could be decreased to 350 mg and still induce reproducibly stable mixed chimerism and donor-specific tolerance in 100% of the treated mice. However, the effect of this decrease in the admistered dose of anti-CD3 should further be explored on the level of cytokine production in the recipients.
It is not clear why lower T-cell suppression can be applied in combination with Treosulfan. However, we do not exclude the possibility that Treosulfan might delete proliferating (ie donor-reactive) T cells via DNA alkylation and DNA interstrand crosslinking followed by DNA fragmentation and cell death. The dose of anti-CD3 could be reduced more in combination with a high dose of Treosulfan and transplantation over a complete MHC barrier than in combination with a lower dose Treosulfan and haploidentical BMT. We hypothesize that a certain dose of Treosulfan is needed to deplete peripheral donorreactive T cells. In experiments in which BMT across haploidentical barriers is applied, this dose may have been too low to induce this depletion, whereas the higher dose of Treosulfan that is administered prior to BMT across complete MHC barriers might have been sufficient to induce this depletion.
Recently, we have shown that the most likely mechanism via which donor-specific tolerance is induced and maintained in our BMT model is clonal deletion of T cells. 28 We demonstrated this in a superantigen-based mouse model in which the T-cell repertoire was shaped by the presence of I-E þ cells in donor BM. In the present study, where Treosulfan replaces TBI, we again found clonal deletion of Vb5 þ and Vb11 þ T cells (data not shown). Clonal deletion of donor-reactive cells is the most robust form of donorspecific tolerance and may be potentially more durable and resilent than other mechanisms of tolerance, since T-cell clones reactive to the donor are absent.
We conclude that Treosulfan is a very interesting candidate drug, not only in the treatment of ovarian cancer, but also for more experimental clinical therapies that include HSC transplantation, 20, 21, 29 for example, severe autoimmune diseases or the long-term induction of donor-specific tolerance in organ transplantation. 
